Human health is inextricably linked to planetary health. As the impacts of climate change are being experienced around the globe, the impacts on global health are becoming more and more clear.
Heat events and …
- At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs. bosutinib in patients previously treated with two or more tyrosine-kinase inhibitors (TKIs)1
- Despite advances in chronic myeloid leukemia (CML) care, many patients are at risk of disease progression, and sequential TKI therapy may be associated with increased resistance and intolerance2-7
- By specifically targeting the ABL myristoyl pocket, STAMP inhibition has …
- Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma
- Tafinlar + Mekinist remains an effective treatment option based on previously reported large, Phase III clinical trials1,2
- Spartalizumab development program continues, investigating the immunotherapy in combination with other anti-cancer agents
Basel, August 22, 2020 — Novartis announced today that the Phase III COMBI-i study evaluating the investigational immunotherapy …
As an expert in infectious diseases, Jennifer Leeds could see the storm brewing. When COVID-19 began to emerge – first in Asia, then in Europe – she could see that its relative ease transmitting from person to person, along with the lack of tests and preventions or treatments for infection, made the virus a credible threat to humanity. Knowing that a pandemic was likely coming made watching the crisis unfold no less heartbreaking. Fortunately, as a member of the Novartis Business Development & Licensing (BD&L) department, she was in a position to try to help.
…
- Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple sclerosis (RMS)1
- Approval based on two Phase III ASCLEPIOS studies demonstrating significant reductions in risk of relapses, confirmed disability progression, Gd+ T1 brain lesions and new/enlarging T2 lesions1
- Kesimpta may halt new disease activity in RMS patients as shown in a post hoc analysis, with 47.0% and 87.8% of …
Basel, August 17, 2020 — Novartis welcomes the decision by the US District Court for the District of Delaware to uphold the validity of the Gilenya® (fingolimod) dosage regimen patent, as our intellectual property reflects the innovation and investment needed to invent and develop treatments that improve and extend people’s lives.
The decision also holds that the generic fingolimod product proposed by HEC Pharm Co., Ltd. and HEC Pharm USA Inc. (“HEC”) in its Abbreviated New Drug Application (ANDA) will infringe the dosage regimen patent (US …
Marc Boutin, currently CEO of the National Health Council (NHC), brings 20 years of international leadership experience in health advocacy, policy and legislation. Throughout his professional career, he has focused on creating access to care through …
- EC approves Xolair® (omalizumab) as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, the first anti-immunoglobulin E antibody approved in this indication1
- Chronic rhinosinusitis with nasal polyps is a debilitating condition for many patients, with symptoms including nasal blockage, difficulty breathing and sleeping, and loss of sense of smell, which reduce quality of life2–4
- Approval builds on well-established efficacy and safety record of Xolair, which has over 1.3 million …
Kalwe, India: staying on site to ensure leprosy drug production
Multidrug therapy (MDT) was a major breakthrough in the fight against leprosy and remains the cornerstone of the global leprosy elimination strategy. The Sandoz Kalwe site, located north of Mumbai on India’s west coast, manufactures and supplies MDT to the World Health Organization as part of the Novartis pledge to donate MDT medicines to eliminate leprosy. But in March, manufacturing and supplying MDT became a …
- Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis1
- ASCLEPIOS I and II demonstrated significant reductions in risk of relapses, confirmed disability worsening and profound reduction of active or new brain lesions1
- The US Food and Drug Administration and European Medicines Agency are currently reviewing ofatumumab for the treatment of relapsing forms of multiple …